Session » Spondyloarthritis Including PsA – Treatment Poster I: AxSpA
-
Abstract Number: 0403
Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study
-
Abstract Number: 0404
Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial
-
Abstract Number: 0405
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Baseline BMI: A Post Hoc Analysis of Phase 2 and Phase 3 Trials
-
Abstract Number: 0406
Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?
-
Abstract Number: 0407
Effect of Biologics in MRI/CRP Subgroups of Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
-
Abstract Number: 0408
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
-
Abstract Number: 0409
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
-
Abstract Number: 0412
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
-
Abstract Number: 0414
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
-
Abstract Number: 0415
The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis
-
Abstract Number: 0416
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
-
Abstract Number: 0417
Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review
-
Abstract Number: 0418
Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
-
Abstract Number: 0419
Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Objective Signs of Inflammation at Baseline
-
Abstract Number: 0420
What Does It Mean – A Good Response to NSAIDs? A Systematic Comparison of Patients with Axial Spondyloarthritis and Controls with Chronic Back Pain
-
Abstract Number: 0421
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial
-
Abstract Number: 0422
Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort
-
Abstract Number: 0423
Direct and Indirect Effect of TNFi on BASMI Components in People with Axial Spondyloarthritis: A Longitudinal Study
-
Abstract Number: 0424
The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort
-
Abstract Number: 0425
Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
-
Abstract Number: 0426
The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
-
Abstract Number: 0427
Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study
-
Abstract Number: 0428
Difficult to Treat Spondyloarthritis: Patients with a High Biologic Switch Rate and the Factors Influencing It; A Real World as Clinic Experience
-
Abstract Number: 0429
No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis